News | August 11, 2021
Marksons Pharma PAT at Rs 62.6 cr. for Q1FY22
The company has tied up with OrbiMed as a financial partner for global reach
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Subscribe To Our Newsletter & Stay Updated
